Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
- 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”
November 26, 2020
- MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
- JPMA Concerned about COVID-19 Pandemic’s Impact on Efforts to Improve Distribution
November 26, 2020
- MHLW Formulates Package Strategy for SaMD Commercialization, Eyes Sakigake Scheme
November 26, 2020
- Drug Price Negotiations in 1st Half Delayed by COVID-19 Impact: JPWA Survey
November 25, 2020
- Single Product, Single Price Trade Ratio in H1 FY2020 Virtually Flat: MHLW
November 25, 2020
- Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
November 25, 2020
- MHLW to Issue COVID-19 Immunity Certificate: Parliamentary Secretary
November 25, 2020
- MHLW to Prepare 7,500 More Freezers for COVID-19 Vaccine Storage at Medical Institutions
November 25, 2020
- MHLW Weighing Fixed Brand Vaccine Allocation for Each Medical Institution: Official
November 25, 2020
- COVID-19 Vaccine Distribution Will Be Undertaken by Wholesalers with Certain Track Records: Minister
November 25, 2020
- Takeda’s ALK Med, 1st Male Indication for HPV Vaccine, Lynparza’s Pancreatic Cancer Use Up for PAFSC Review on Dec. 4
November 24, 2020
- 1st Humira Biosimilar to Join NHI Price List on Nov. 25
November 24, 2020
- MHLW to Evaluate Suspected Adverse Reactions to COVID-19 Vaccines More Frequently than Usual: Minister
November 24, 2020
- Govt Won't Disclose Plans for Excess COVID-19 Vaccines: Health Minister
November 24, 2020
- LDP Going into Tax Reform Debate for FY2021
November 20, 2020
- Fully Implement Off-Year Drug Re-Pricing: LDP Fiscal Consolidation HQ
November 20, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- PAFSC Likely to Skip Review of Ono’s Cancer Cachexia Drug Yet Again
November 20, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…